Cannabix Technologies Announces Detection of Methamphetamine and Amphetamine in Human Breath

Vancouver, British Columbia, July 2, 2026 -- Cannabix Technologies Inc. (CSE: BLO) (OTCID: BLOZF) (Frankfurt: 8CT) (the “Company” or “Cannabix”) developer of marijuana and alcohol breath testing technologies for workplace safety and law enforcement, announces the detection of methamphetamine and amphetamine compounds in human breath samples tested with the Cannabix Marijuana Breath Test ("MBT"). Human breath samples were collected using the Cannabix Breath Collection Unit (“BCU”) and were analyzed by Omega Laboratories Inc. ("Omega") utilizing liquid chromatography-mass spectrometry ("LC-MS").

Methamphetamine & Amphetamine Detection in Breath Represents a Significant New Opportunity

The detection of methamphetamine and amphetamine compounds in breath is a significant new development that further validates the sensitivity and performance of the Cannabix MBT (consisting of the Cannabix BCU (Figure 1), disposable Breath Cartridges, and the Laboratory-Developed Test Method by Omega).  Amphetamine-class stimulants are generally present in breath at extremely low concentrations, making reliable capture and laboratory identification technically challenging. Unlike conventional biological matrices such as urine, breath contains only trace amounts of non-volatile drug compounds carried within microscopic aerosol particles originating from the respiratory tract.  

The Company believes these findings support the potential expansion of the Cannabix MBT beyond THC.  The ability to identify amphetamine-class stimulants in breath, alongside a legally defensible chain of custody and analytical process, could create significant additional value for workplace safety, transportation, industrial, and law enforcement customers seeking non-invasive and scientifically defensible testing solutions.

Rav Mlait, CEO of Cannabix Technologies, stated, “Detecting methamphetamine and amphetamine in human breath is a significant development for Cannabix. These compounds are typically present at extremely low concentrations in exhaled breath, requiring highly efficient sample collection and sophisticated analytical techniques. These early findings support our belief that Cannabix’s breath collection technology may have applicability beyond cannabis and could ultimately create significant additional value for customers seeking comprehensive breath-based drug testing solutions.”

Methamphetamine and amphetamine are illicit drugs and pose significant safety concerns across transportation, construction, resource extraction, manufacturing, and other safety-sensitive environments. The ability to detect such substances using breath-based testing technology could provide organizations with a new tool for supporting impairment management